Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy

Shama R. Mehta, Eugene F. Yen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Clostridioides difficile infection (CDI) has had a devastating impact worldwide with significant rates of mortality, especially among the elderly. Despite effective antibiotics, the incidence of recurrent CDI (rCDI) is increasing and more difficult to treat with antibiotics alone. Fecal Microbiota Transplantation (FMT) has emerged as a consistently effective treatment for rCDI. Mechanisms for FMT are not entirely understood, but remain an area of active investigation. There have been recent safety reports with the use of FMT regarding transmission of pathogens in a few patients that have led to serious illness. With appropriate screening, FMT can be safely administered and continue to have a significant impact on eradication of rCDI and improve the lives of patients suffering from this disease. In this review, we summarize current treatments for CDI with a focus on microbiota-based therapies used for antibiotic refractory disease.

Original languageEnglish (US)
Pages (from-to)197-207
Number of pages11
JournalTranslational Research
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Physiology (medical)
  • Biochemistry, medical


Dive into the research topics of 'Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy'. Together they form a unique fingerprint.

Cite this